Who we are
Peel Therapeutics is on an expedition to unlock nature’s secrets and overcome life-threatening conditions. These evolutionary outliers rarely make their way to patients, and we are determined to change that.
We are an evolutionary-inspired, clinical-stage biotech company developing medicines to transform patients’ lives. Peel (the Hebrew word for “elephant”) launched with our focus on cancer-fighting proteins in elephants and we quickly recognized the power of using evolution’s solutions to treat and prevent disease. In addition to developing elephant p53 (EP53) nanoparticles for the treatment of cancer, our team is advancing additional therapies derived from nature’s superabilities to treat cancer and immune diseases.
Our Approach
Life science R&D has produced countless new therapies with positive health outcomes, but it cannot compare to ages of evolutionary history. With deep knowledge of evolutionary biology and comparative genomics, we use Darwin.AI™ to seek out novel targets and molecules in nature that have exceeded what we thought was biologically possible. We then apply our drug development expertise to rapidly translate this into evolutionary medicines and advance our therapeutic pipeline to treat a spectrum of devastating conditions, including cancer and immune diseases. Our therapy’s efficacy is derived from its validation in 100 million years of evolutionary development — maximizing impact while minimizing side-effects.
Our Mission
Peel Therapeutics’ mission is to unlock evolutionary biology to improve patient lives.
Our Vision
Peel Therapeutics aims to develop safe and highly effective medicines that transform patient care.
Our Leadership
Our multidisciplinary team across the US and Israel offers a unique blend of scientific and medical expertise, enthusiasm and curiosity. We hail from all corners of industry, academia, and clinical medicine, and the patients we serve are the driving force behind the work we do every day.